Recently, accumulating studies have found that ACSL4 dysregulation is related to a great number of malignant tumors. The purpose of the present study was to explore the relationship between ACSL4 expression level and clinical prognosis of hepatocellular carcinoma (HCC) patients.
Background
Hepatocellular carcinoma (HCC) as one of the most common malignancies of the digestive tract, it is the third cause of cancer death worldwide [1] , and it ranks second in China's malignant tumor mortality incidence [2] . Most HCC patients miss the chance of receiving radical resection or liver transplantation due to their disease being diagnosed at a late stage [3] . Therefore, it is helpful to develop diagnostic and therapeutic targets through identification of genes which are differentially expressed in HCC.
Bioinformatics is a powerful tool for mining tumor differential genes. In early studies, it was found that the long chain fatty acyl-CoA ligase 4 (ACSL4) gene was highly expressed in HCC compared with normal tissues. ACSL4, also known as FACL4, was initially identified as its mutation in non-specific X-linked mental retardation in 2002 [4] . Maloberti et al. [5] found that ACSL4 possessed a substrate preference for eicosapentaenoic acid and arachidonic acid (AA). More interestingly, the level of intracellular ACSL4 protein can be altered in turn by the amounts of free AA [6] . So far, it has been proven that the ACSL4 dysregulation is related to a great number of diseases including diabetes [7] , atherosclerosis [8] , obesity [9] , and malignant tumors [10] [11] [12] [13] [14] [15] [16] [17] . In a previous study, Sung et al. [10, 11] found that ACSL4 was overexpressed in HCC cell lines and tissues compared to normal cell lines. However, the relationship between ACSL4 expression level and clinical prognosis of HCC patients remains largely unclear.
Therefore, in the present study, immunohistochemical staining was done to examine the expressions of ACSL4 in 116 paired HCC and adjacent normal tissue samples. In addition, ACSL4 expression in HCC and its relationships with patients' clinicopathological factors and prognosis were investigated.
Material and Methods

Bioinformatics prediction
First, the Oncomine database (https://www.oncomine.org/resource/login.html) was used to predict the ACSL4 mRNA expression levels in HCC and normal tissues. Then the Cancer Genome Atlas (TCGA) database was used to predict the relationship between expression levels of ACSL4 mRNA and clinical prognosis of HCC patients.
Patients and samples
One hundred and sixteen cases of HCC patients who had received the curative operation at Anhui Provincial Hospital from January 2009 to June 2013 were selected. We used the tumor-node-metastasis (TNM) classification (sixth edition) of the Union for International Cancer Control (UICC) to evaluate tumor stage. The detailed information on ACSL4 protein expression and other clinicopathological factors (such as gender and age) are listed in Table 1 . The study was approved by the Ethics Committee of Anhui Provincial Hospital and all patients signed the written informed consent.
Immunohistochemistry and analysis
Immunohistochemistry was performed according to the manufacture protocol. After the sections were treated with dewaxing, antigen repair, and serum sealing, ACSL4 antibody (1: 500, ab110007, Abcam, UK) was added at 4°C overnight. The next day, after rewarming for 45 minutes, PBS was used to wash the sections, and then the sections were incubated at room temperature. The staining results were observed by microscope and immunohistochemical scores were calculated as described in a previous report [18] . 
Results
ACSL4 high expression in HCC
We first used the Oncomine database to find that ACSL4 mRNA expression level was significantly higher in HCC tissues than that in normal tissues ( Figure 1 , p all <0.001). The results were consistent with those from the TCGA database ( Figure 2A ). Then, in order to verify the real expression level of ACSL4 in HCC, immunohistochemistry was selected to examine the Normal (10) HCC ( protein level of ACSL4 in 116 paired HCC and adjacent normal tissues ( Figure 3 ). ACSL4 protein staining was mainly located in the cytoplasm ( Figure 3A ). ACSL4 positive expression rate was 70.7% (82/116) in HCC tissues ( Table 4 . Cox regression analysis of ACSL4 and other clinicopathological parameters in HCC patients. listed in Table 2 . ACSL4 differential expression level was significantly related to Edmondson grade (p=0.010), AFP (p=0.001) and TNM stage (p=0.012).
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Correlation between ACSL4 expression and survival of HCC patients
Through mining the TCGA database, we found HCC patients with ACSL4 mRNA high expression had lower survival time than those with ACSL4 mRNA low expression ( Figure 2B ). Then, our own immunochemical results were consistent with the predictive findings. Survival analysis revealed that ACSL4 expression levels were significantly associated with the survival time of HCC patients. Moreover, compared to those with ACSL4 protein low expression levels, both OS and DFS time were remarkably reduced in HCC patients with ACSL4 high expression levels (p=0.001, Figure 4A and p=0.000, Figure 4B , respectively).
Prognostic value of ACSL4 expression in HCC patients
Initially, we used univariate analysis to reveal that ACSL4 expression, Edmondson grade and TNM stage had statistically prognostic influences on both OS and DFS (Table 3 ). In addition, Cox multivariate analysis demonstrated that ACSL4 expression was the only independent prognostic factor for both OS and DFS (both p values=0.001, Table 4 ).
Discussion
There has been accumulating evidence from studies demonstrating that ACSL4 is overexpressed in parts of malignant tumors such as liver [10, 11] , prostate [12, 13] and breast cancer [13] [14] [15] [16] . In these findings, ACSL4 is reported to perform an oncogene role in promoting tumorigenesis and metastasis. While on the other hand, Ye et al. [17] recently found that ACSL4 may serve as a tumor suppressor gene in gastric cancer possibly involving FAK and P21 signaling. As for HCC, in order to verify the exact role of ACSL4 and explore the relationship between its expression and the prognosis of HCC patients, the present study was designed and completed.
We first used the Oncomine and TCGA databases to reveal that ACSL4 mRNA expression level was significantly higher in HCC tissues than that in normal tissues. Then, in order to validate this phenomenon, 116 cases of paired HCC and normal tissues were selected. Immunochemical results showed that ACSL4 positive expression rate was 70.7% (82/116) in HCC tissues. Compared to those in the adjacent normal tissues, ACSL4 protein expression levels were remarkably higher in HCC tissues. These findings were consistent with the bioinformatics analysis and a report by Sung et al. [10, 11] . Moreover, ACSL4 differential expression level was significantly related to Edmondson grade (p=0.010), AFP (p=0.001) and TNM stage (p=0.012). Therefore, the above results suggest a key role for ACSL4 in HCC progression and development.
Though Sung et al. [10, 11] reported that ACSL4 was overexpressed in HCC tissues and cell lines, whether it has prognostic significance in HCC has remained unclear. So next, we used the TCGA database to predict that HCC patients with ACSL4 mRNA high expression level had worse OS than those with ACSL4 mRNA low expression level. This finding was validated by our own experimental data. Kaplan-Meir analysis showed that HCC patients with ACSL4 protein high expression had significantly reduced OS and DFS than those with ACSL4 protein low expression. Moreover, both univariate and multivariate analyses demonstrated that ACSL4 was the only independent unfavorable predictor of OS and DFS in HCC patients.
There were several limitations to our study that should be noted. First, this was a retrospective study, possibly resulting in a selective bias. Second, only immunohistochemistry (a semiquantitative method) was used to detect the ACSL4 protein expression. Finally, we did not explore the exactly underlying molecular mechanisms in this study, which will be elucidated in future studies.
Conclusions
Collectively, our present study demonstrated that ACSL4 was overexpressed in HCC and patients with high expression level of ACSL4 had unfavorable prognosis. ACSL4, as an independent adverse prognostic parameter, will be a new potential therapeutic target for HCC.
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